The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.672503
AFN 63.999633
ALL 81.13116
AMD 364.066319
ANG 1.790365
AOA 917.999554
ARS 1524.997501
AUD 1.439429
AWG 1.8025
AZN 1.699887
BAM 1.725719
BBD 2.018882
BDT 123.247965
BGN 1.683441
BHD 0.377906
BIF 3005.722202
BMD 1
BND 1.279885
BOB 12.063778
BRL 5.184055
BSD 1.002338
BTN 96.076978
BWP 14.120969
BYN 3.01672
BYR 19600
BZD 2.01597
CAD 1.42459
CDF 2310.000003
CHF 0.836205
CLF 0.024656
CLP 973.539878
CNY 6.70475
CNH 6.71436
COP 3314.79
CRC 457.846208
CUC 1
CUP 24.056893
CVE 97.29465
CZK 21.580966
DJF 178.497375
DKK 6.601103
DOP 59.602065
DZD 133.919964
EGP 51.941199
ERN 15
ETB 163.729916
EUR 0.88295
FJD 2.24875
FKP 0.756991
GBP 0.75445
GEL 2.60498
GGP 0.756991
GHS 11.732889
GIP 0.756991
GMD 74.000372
GNF 8750.000468
GTQ 7.658099
GYD 209.730789
HKD 7.84665
HNL 26.909604
HRK 6.6528
HTG 131.186306
HUF 323.419643
IDR 17937
ILS 3.07365
IMP 0.756991
INR 95.96915
IQD 1313.138889
IRR 1693792.502544
ISK 120.969796
JEP 0.756991
JMD 158.635902
JOD 0.708994
JPY 158.143502
KES 129.719972
KGS 87.4487
KHR 4065.101628
KMF 435.000056
KPW 900.000318
KRW 1360.175049
KWD 0.30903
KYD 0.835337
KZT 440.918897
LAK 22497.408184
LBP 89762.385847
LKR 331.231884
LRD 171.912363
LSL 16.416191
LTL 2.95274
LVL 0.60489
LYD 6.411082
MAD 9.723465
MDL 17.796797
MGA 4402.876428
MKD 54.331282
MMK 2099.600314
MNT 3599.1704
MOP 8.102072
MRU 40.144704
MUR 47.75987
MVR 15.449965
MWK 1738.121498
MXN 18.08776
MYR 4.086498
MZN 63.909596
NAD 16.41706
NGN 1326.860227
NIO 36.892099
NOK 9.633325
NPR 153.717739
NZD 1.77802
OMR 0.384505
PAB 1.002374
PEN 3.450819
PGK 4.536992
PHP 62.741981
PKR 277.681916
PLN 3.85205
PYG 5864.031411
QAR 3.65434
RON 4.657014
RSD 103.796978
RUB 83.375041
RWF 1480.037058
SAR 3.759293
SBD 8.032647
SCR 13.836223
SDG 601.505977
SEK 10.01845
SGD 1.27922
SHP 0.755829
SLE 24.649875
SLL 20969.491881
SOS 572.815106
SRD 37.621502
STD 20697.981008
STN 21.617329
SVC 8.77073
SYP 13002.000254
SZL 16.407994
THB 33.620498
TJS 9.232161
TMT 3.51
TND 2.97262
TOP 2.40776
TRY 49.032203
TTD 6.800164
TWD 31.937496
TZS 2640.002984
UAH 44.775489
UGX 3929.198542
UYU 40.386126
UZS 11858.028368
VES 857.98905
VND 25966
VUV 119.008285
WST 2.76852
XAF 579.17706
XAG 0.016353
XAU 0.000240041575
XCD 2.70255
XCG 1.806559
XDR 0.707052
XOF 579.17706
XPF 105.230186
YER 236.396786
ZAR 16.44243
ZMK 9001.20083
ZMW 19.596771
ZWL 321.999592
SSP 5712.591896
MXV 2.047495
  • RYCEF

    0.4000

    19.71

    +2.03%

  • CMSC

    0.0000

    20.4

    0%

  • BTI

    0.4200

    56.05

    +0.75%

  • BP

    0.2800

    44.43

    +0.63%

  • RBGPF

    1.6000

    67

    +2.39%

  • RIO

    -0.1500

    94.41

    -0.16%

  • AZN

    -0.4300

    166.15

    -0.26%

  • GSK

    0.4600

    49.7

    +0.93%

  • BCE

    -0.4100

    20.56

    -1.99%

  • NGG

    -0.2500

    75.24

    -0.33%

  • VOD

    -0.0400

    16.58

    -0.24%

  • RELX

    -0.4500

    33.07

    -1.36%

  • BCC

    -0.5500

    76.59

    -0.72%

  • CMSD

    -0.0300

    20.27

    -0.15%

  • JRI

    -0.2500

    10.77

    -2.32%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM